IMMX
Immix Biopharma Inc

4,030
Loading...
Loading...
News
all
press releases
Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock?
Zacks·4mo ago
News Placeholder
More News
News Placeholder
IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips IMMX stock results show that Immix Biopharma missed analyst estimates for earnings per share the fourth quarter of 2023. The post IMMX...
InvestorPlace·1y ago
News Placeholder
Immix Biopharma, Inc. (NASDAQ:IMMX) Sees Large Growth in Short Interest
Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) saw a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 316,600 shares, a...
Zolmax·1y ago
News Placeholder
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) ( ImmixBio , Company , We or Us or IMMX ), a clinical-stage biopharmaceutical company trailblazing...
Globe Newswire·2y ago
News Placeholder
Immix Biopharma Announces Be Proactive in AL AL Amyloidosis Awareness Initiative
Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words Immix Biopharma Announces Be Proactive in AL AL Amyloidosis Awareness...
Globe Newswire·2y ago
News Placeholder
Immix Biopharma 12 Month Review Progress Update
LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced...
Globe Newswire·2y ago
News Placeholder
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
European Orphan Drug Designation ( ODD ) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for EU...
Globe Newswire·2y ago
News Placeholder
Immix Biopharma 5.5M share priced at $2.71
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
Immix Biopharma Announces Proposed Public Offering of Common Stock
LOS ANGELES, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (the Company ), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease...
Globe Newswire·2y ago
News Placeholder
Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
LOS ANGELES, CA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ( Immix Biopharma , Company , We or Us , Nasdaq:IMMX), a clinical-stage biopharmaceutical company trailblazing cell...
Globe Newswire·2y ago

Latest IMMX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.